Local and remote matrix responses to chondrocyte-laden collagen scaffold implantation in extensive articular cartilage defects.

This research article explores the use of chondrocyte-laden collagen scaffolds in treating extensive cartilage defects in horses, finding evidence of improved aggrecan content but not a significant difference in type II collagen proportions, suggesting limited efficacy of collagen scaffolds for large defect repair.

Research Objective and Methodology

• The primary objective of this research focused on testing the effectiveness of chondrocyte-laden collagen scaffolds for repairing extensive articular cartilage defects in horses. These scaffolds were filled with chondrocytes, the cells that produce and maintain the extracellular matrix of cartilage.
• Using the arthroscopic technique, a chondrocyte-collagen culture product was implanted in the cartilage defects in the femoropatellar joint of 12 horses. For comparison, ungrafted control defects were also formed in the opposite joint of the same horses.
• This study kept a close check on the repair sites, adjacent cartilage, and remote cartilage within each joint, which they analyzed biochemically in groups of six horses, at 4 and 8 months after implant.

Research Outcomes

• The researchers assessed the relative proportions of the type II collagen (the primary structural protein in cartilage) in both grafted and ungrafted defects.
• There were no significant differences observed in the proportions of type II collagen between grafted and ungrafted defects, eight months post-surgery. This was determined using the ratio of cyanogen bromide cleavage products alpha 1(II)CB10/alpha 2(I)CB3,5, which was 31.57 +/- 2.76% and 26.88 +/- 2.76%, respectively.
• The content of aggrecan, a major component of the cartilage extracellular matrix, showed significant improvement in the grafted defects. This was 85.61 +/- 6.51 and 74.91 +/- 10.31 micrograms/mg dry weight. This essentially meant that the chondrocyte grafting in collagen scaffold vehicles had a positive effect on aggrecan content in extensive cartilage defects and even the surrounding normal cartilage.
• Nonetheless, even with the improved aggrecan content in grafted defects, the study found that there was a continued disparity in the aggrecan content between the repaired tissue and normal cartilage.

Conclusion

• Though there was a notable benefit of improved aggrecan content in and around repaired defects, the study concludes that the use of collagen scaffolds for chondrocyte grafting in large cartilage defects seem to have limited utility.
• This limitation is due to a low proportion of type II collagen in grafted defects, which didn’t show any significant improvement when compared to ungrafted defects. This is crucial because type II collagen is paramount to the structural integrity of cartilage.